Flow cytometry analysis showed that priming of the tumor microenvironment with tranilast enhanced the antitumor responses of immunotherapy as indicated by the accumulation of CD4+ and CD8+ T cells and the concomitant increase in the cytotoxic to regulatory T cell ratio (Fig. 5, Supplementary Fig. 12). The gene discussed is CD8A; the disease is neoplasm.